AstraZeneca, Syndax in Cancer Clinical Trial Pact
AstraZeneca and Syndax Pharmaceuticals, a Waltham, Massachusetts-headquartered clinical-stage biopharmaceutical company developing cancer therapies, have formed a clinical pact to evaluate AstraZeneca’s durvalumab, a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in combination with SNDX-6352, Syndax’s monoclonal antibody inhibitor of colony-stimulating factor 1 receptor, across a variety of solid tumors.
Under the agreement, AstraZeneca and Syndax will collaborate on a non-exclusive basis to evaluate the combination of the two drugs in multiple solid tumor types. Syndax expects to initiate a Phase Ib study in the first half of 2018 to establish the safety and recommended dose regimen of SNDX-6352 in combination with durvalumab. Data from this study will enable both companies to sponsor, design, and initiate subsequent Phase II studies aimed at exploring the safety and efficacy of the combination across a number of defined tumor types.